Selected article for: "animal model and antibody response"
Author: Dey, Ayan; Chozhavel Rajanathan, T.M.; Chandra, Harish; Pericherla, Hari P.R.; Kumar, Sanjeev; Choonia, Huzaifa S.; Bajpai, Mayank; Singh, Arun K.; Sinha, Anuradha; Saini, Gurwinder; Dalal, Parth; Vandriwala, Sarosh; Raheem, Mohammed A.; Divate, Rupesh D.; Navlani, Neelam L.; Sharma, Vibhuti; Parikh, Aashini; Prasath, Siva; Sankar Rao, M.; Maithal, Kapil
Title: Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
  • Cord-id: d033uhae
  • Document date: 2021_6_1
    • ID: d033uhae
    Snippet: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 million cases of infection and over 2 million deaths. Huge efforts were undertaken to bring the COVID-19 vaccines in clinical development, so that it can be made available at the earliest, if found to be efficacious in the trials. We developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene e
    Document: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in China in year 2019 and spread rapidly across the globe within 5 months, causing over 96 million cases of infection and over 2 million deaths. Huge efforts were undertaken to bring the COVID-19 vaccines in clinical development, so that it can be made available at the earliest, if found to be efficacious in the trials. We developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. The S protein of the virus includes the receptor binding domain (RBD), responsible for binding to the human angiotensin converting enzyme (ACE-2) receptor. The DNA plasmid construct was transformed into E. coli cells for large scale production. The immunogenicity potential of the plasmid DNA has been evaluated in mice, guinea pig, and rabbit models by intradermal route at 25, 100 and 500 µg dose. Based on the animal studies proof-of-concept has been established and preclinical toxicology (PCT) studies were conducted in rat and rabbit model. Preliminary animal study demonstrates that the candidate DNA vaccine induces antibody response including neutralizing antibodies against SARS-CoV-2 and also elicited Th-1 response as evidenced by elevated IFN-γ levels.

    Search related documents:
    Co phrase search for related documents
    • active vaccine and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • acute respiratory syndrome and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and live vaccination: 1, 2, 3
    • acute respiratory syndrome and local concentration: 1
    • acute respiratory syndrome and localization expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and long term antibody response: 1, 2
    • acute respiratory syndrome and long term immunogenicity: 1, 2, 3
    • acute respiratory syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung injury disease severity: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lysine residue: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars cov respiratory syndrome coronavirus and live vaccination: 1, 2
    • acute sars cov respiratory syndrome coronavirus and local concentration: 1
    • acute sars cov respiratory syndrome coronavirus and localization expression: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and long term antibody response: 1, 2
    • acute sars cov respiratory syndrome coronavirus and long term immunogenicity: 1, 2
    • acute sars cov respiratory syndrome coronavirus and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lung injury disease severity: 1
    • acute sars cov respiratory syndrome coronavirus and lysine residue: 1, 2, 3, 4, 5